Culture PCR Species Risk Factors Site Empiric Therapy Targeted Therapy Surgery IFD Final Response Patient alive Year of Infection
Culture available Trichosporon asahii Corticosteroids, Cancer (ALL), Chemotherapy, Neutropenia Blood, Lungs Liposomal amphotericin B Liposomal amphotericin B, Voriconazole Deterioration or failure No 2009
Culture available Trichosporon asahii Corticosteroids, Chronic renal disease, Solid organ transplantation Blood Fluconazole Complete Response No 2009
Culture available Trichosporon asahii Corticosteroids, Immunosuppression, Cancer (ALL), Chemotherapy, Hematopoietic stem cell transplantation (HSCT), ICU, Neutropenia Blood Amphotericin B deoxycholate, Voriconazole Deterioration or failure No 2009
Culture available Trichosporon asahii ICU, Major surgery Blood, Other: Wound infection Fluconazole, Caspofungin Complete Response Yes 2006
Culture available Trichosporon asahii Cancer (Lymphoma), Chemotherapy, Neutropenia Blood, Other: Knee articulation Fluconazole Deterioration or failure No 2006
Culture available Trichosporon asahii Immunosuppression, Cancer (CML), Hematopoietic stem cell transplantation (HSCT) Blood Fluconazole Complete Response Yes 2007
Trichosporon asahii Corticosteroids, Alcoholism, Chronic liver disease, Chronic renal disease, ICU, Solid organ transplantation Blood Fluconazole, Caspofungin, Amphotericin B lipid complex Amphotericin B lipid complex, Caspofungin, Itraconazole Partial Response No 2003
Trichosporon asahii Cancer (ALL), Chemotherapy, Neutropenia Blood, Kidneys, Liver, Spleen Liposomal amphotericin B Voriconazole Deterioration or failure No 2005
Culture available Trichosporon asahii Cancer (AML), Chemotherapy, Neutropenia Blood Posaconazole solution, Caspofungin Caspofungin Cholecystektomie Deterioration or failure No 2009
Culture available Trichosporon asahii No risk factor identified Paranasal sinus(es) Voriconazole Functional endoscopic sinus surgery Complete Response Yes 2011
Trichosporon asahii Immunosuppression, Cancer (ALL), Chemotherapy, Hematopoietic stem cell transplantation (HSCT), Neutropenia Blood, CNS, Kidneys, Lungs Deterioration or failure No 2011
Trichosporon asahii Chemotherapy Blood Caspofungin Voriconazole Deterioration or failure No 2011
Trichosporon asahii Cancer (Lymphoma), Chemotherapy, Neutropenia Blood, Bones, Deep soft tissues, Eyes, Liver, Spleen, (First only blood, later dissemination to organs) Caspofungin Caspofungin, Voriconazole Partial Response Yes 2010
Trichosporon asahii Cancer (AML), Chemotherapy, Neutropenia Blood, Lungs Posaconazole Complete Response Yes 2011
Trichosporon asahii Immunosuppression, Cancer (ALL), Hematopoietic stem cell transplantation (HSCT) Blood, CNS Caspofungin Voriconazole Deterioration or failure No 2013
Trichosporon asahii Alcoholism, Chronic liver disease, ICU CNS Fluconazole Complete Response Yes 2012
Culture available Trichosporon asahii Alcoholism, Chronic liver disease Blood Deterioration or failure No 2014
Trichosporon asahii Cancer Other (Ewing's sarcoma), Hematopoietic stem cell transplantation (HSCT) - Autologous Blood, Kidneys, Lungs, Disseminated Amphotericin B lipid complex, Fluconazole, Caspofungin Progression No 2015
Culture available Trichosporon asahii Corticosteroids, Immunosupression, Cancer (Acute Leukemia), Chemotherapy, Neutropenia, Other: CVC Blood, Disseminated Amphotericin B liposomal Voriconazole Complete Response Yes 2017
Culture available Trichosporon asahii Cancer (CML), Hematopoietic stem cell transplantation (HSCT) - Allogeneic, Chemotherapy, Other: CVC Blood, Disseminated Amphotericin B liposomal Amphotericin B liposomal, Voriconazole Progression No 2014
Please note that there have been more results matching your query! We only show 20 out of 43 found due to security reasons. Feel free to contact us if you have any further questions!

Principle Investigator:
Prof. Oliver A. Cornely, MD, FACP, FIDSA, FAAM, FECMM, Cologne, Germany
Project Manager:
Danila Seidel, PhD, Cologne, Germany
Coordinating physician:
Maria J. G. T. Vehreschild, MD, Cologne, Germany
Epidemiology & Statistics:
J. Janne Vehreschild, MD, FECMM, Cologne, Germany